Tanja Denise De Gruijl

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Lava Therapeutics N.v., Lava Therapeutics B.v., Dcprime B.v.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tanja Denise De Gruijl. Retrieved from https://idiyas.com/inventor/tanja-denise-de-gruijl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Amsterdam, NL (2013 - 2023)
Utrecht, NL (2022 - 2024)

Company Filing History:

4 out of 5

Lava Therapeutics N.v.

patents

2 out of 2

Lava Therapeutics B.v.

Orca Therapeutics B.v.

patent

Years Active: 2013-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12233096 - Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells (2025-02-25),

2. 12110328 - Single domain antibodies targeting CD1d (2024-10-08),

3. 12077586 - Bispecific antibodies for use in the treatment of hematological malignancies (2024-09-03),

4. 11591394 - Single domain antibodies targeting CD1d (2023-02-28),

5. 11384145 - Immunoglobulins binding human Vγ9Vδ2 T cell receptors (2022-07-12),

6. 10501541 - Single domain antibodies targeting CD1d (2019-12-10),

7. 10501540 - Immunoglobulins binding human Vγ9 Vδ2 T cell receptors (2019-12-10),

8. 8470789 - Method for inducing and accelerating cells (2013-06-25),

Title: Tanja Denise De Gruijl: Innovator in Cancer Treatment

Introduction

Tanja Denise De Gruijl is a prominent inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of cancer treatment through his innovative research and development. With a total of 8 patents, his work focuses on advanced therapeutic methods that target specific biological functions.

Latest Patents

One of his latest patents involves recombinant replication competent viruses that comprise a coding region for glycogen synthase kinase-3 (GSK3). This invention relates to adenoviruses that can replicate in and lyse host cells, providing a method for treating cancer. The patent outlines the use of a coding sequence for GSK3 operably linked to an expression control sequence, which is crucial for effective treatment. This work was funded in part by the European Union Horizon 2020 research and innovation programme, specifically through the Marie-Sklodowska-Curie grant number 643130. Another notable patent focuses on single domain antibodies targeting CD1d. This invention includes compounds and polypeptides that specifically bind to the non-classical MHC protein CD1d, modulating its biological functions. The patent emphasizes the use of single domain antibodies that can effectively interact with CD1d.

Career Highlights

Throughout his career, Tanja has worked with various companies, including Lava Therapeutics N.V. and Lava Therapeutics B.V. His innovative approaches have positioned him as a key figure in the development of new cancer therapies.

Collaborations

Tanja has collaborated with notable coworkers such as Johannes Jelle Van Der Vliet and Renée Cornelia Gerarda De Bruin. Their combined expertise has contributed to the advancement of research in the field of cancer treatment.

Conclusion

Tanja Denise De Gruijl's contributions to cancer research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for innovative treatments that could significantly impact patient care.

Profile summary based on public USPTO records.